Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease
References (31)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Lancet
(1994)- et al.
Cardiovascular disease risk profiles
Am Heart J
(1991) - et al.
High density lipoprotein as a protective factor against coronary heart disease
Am J Med
(1977) - et al.
The variability of serum cholesterol measurements: implications for screening and monitoring
J Clin Epidemiol
(1990) - et al.
Serum cholesterol, lipoproteins, and the risk of coronary heart disease
Ann Intern Med
(1971) The lipid research clinics coronary primary prevention trial results 1: reduction in incidence of coronary heart disease
JAMA
(1984)- et al.
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
JAMA
(1988) - et al.
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
BMJ
(1994) - et al.
Dietary reduction of serum cholesterol concentration: time to think again
BMJ
(1991) - et al.
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
BMJ
(1990)
An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence
Circulation
Cholesterol lowering and mortality: the importance of considering initial level of risk
BMJ
Lower patient's cholesterol now
BMJ
Discontinuation of antihyperlipidaemic drugs-do rates reported in clinical trials reflect rates in primary care settings?
N Engl J Med
The UK-TIA Aspirin Trial: the interim results
BMJ
Cited by (136)
Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus
2021, Revista Colombiana de ReumatologiaCitation Excerpt :For the general population, most risk stratification tools are based on levels of well-established CVRFs such as the Framingham risk score.88 Other examples are the Reynolds score89 which includes high-sensitivity CRP, the Sheffield table system,90 and the SCORE system in Europe. These different methods are similar in their overall low sensitivity and specificity for development of CVD as they exclude various emerging, genetic and otherwise unknown risk factors.
Atherosclerosis in systemic lupus erythematosus
2017, Best Practice and Research: Clinical RheumatologyCitation Excerpt :For the general population, the main risk stratification tools are based on levels of well-established CVD risk factors such as age, sex, serum cholesterol, smoking and blood pressure. The Framingham risk score [31] is the most widely used, but others have also been developed, for example, the Reynolds score [32], which includes high-sensitivity C Reactive Protein (hsCRP) and the Sheffield table system [33]. These different methods are similar in their overall low sensitivity and specificity for development of CVD as they exclude various emerging, genetic and otherwise unknown risk factors.
The Framingham Heart Study's Impact on Global Risk Assessment
2010, Progress in Cardiovascular DiseasesCitation Excerpt :The Sheffield risk tables used in the United Kingdom are derived from the Framingham population. For people without a history of CVD, the table presented in Haq et al40 (1995) shows each combination of age, sex, tobacco smoking status, hypertension, history of diabetes, and LVH on electrocardiogram for which there is a total cholesterol level that confers a 1.5% or greater risk of having a fatal coronary event within 1 year. These are the patients who are predicted to most benefit from statin treatment.
"First-hit" heart attack risk calculators on the world wide web: Implications for laypersons and healthcare practitioners
2008, International Journal of Medical InformaticsA Coronary Heart Disease Risk Score Based on Patient-Reported Information
2007, American Journal of CardiologyGeneration of Knowledge for Clinical Decision Support: Statistical and Machine Learning Techniques
2007, Clinical Decision Support